Request / Find a Test Tool

The National Genomic Test Directories specify which genomic tests are commissioned by the NHS in England, to be delivered by Genomic Laboratory Hubs.

This tool allows clinical teams to search all of the genomic tests available to patients through the National Testing Directory. From here you can find out more details about each test and information about how to order them. These tests can only be ordered by clinical teams, if you are a patient looking to request a test please speak to your clinical team directly.

Li Fraumeni Syndrome

Clinical Indication ID & Name

R216

Li Fraumeni Syndrome

Test Group

Inherited cancer

Test code

R216.1

Test name

N/A

Target genes

TP53

Test scope

n/a

Test method/ technology

Single gene sequencing >=10 amplicons

Optimal Family Structure

n/a

Eligibility Criteria

Living affected individual (proband) where the individual +/- family history meets ONE of the criteria.
The proband has:
1. Rhabdomyosarcoma (≤ 5 years),
2. Rhabdomyosarcoma of embryonal anaplastic subtype (any age)
3. Adrenocortical cancer (any age),
4. Choroid plexus cancer (any age),
5. Breast cancer (≤ 30 years),
6. Triple positive breast cancer (≤ 35 years),
7. Hypodiploid acute lymphoblastic leukaemia (<18 years) 8. SHH medulloblastoma (<18 years) 9. Jaw osteosarcoma (<18 years) 10. ≥2 LFS-related cancers (both occurring ≤ 46 years; two breast cancers not eligible), 11. ≥1 LFS-related cancer with ≥1 first / second degree relative with ≥1 LFS-related cancer (one case ≤ 46 years, the other case ≤ 56 years; two breast cancers not eligible), 12. Cancer with ≥2 first / second degree relatives with cancer; across the family there is: i. 1 individual with sarcoma ≤ 45 years, AND ii. 1 individual with any cancer ≤ 45 years, AND iii. 1 individual with either a sarcoma OR any cancer occurring ≤ 45 years Deceased affected individual (proband) where (i) the individual +/- family history meets one of the above criteria, (ii) appropriate tissue is available (tumour or normal), and (iii) no living affected individual is available for genetic testing LFS-related cancers comprise: soft tissue sarcomas, osteosarcomas, adrenocortical carcinoma, central nervous system tumours and breast cancers. NOTE: The proband's cancer and majority of reported cancers in the family should have been confirmed Genetic testing may occasionally be appropriate outside these criteria following discussion at a specialist MDT with a cancer geneticist present

Test code

R216.2

Test name

N/A

Target genes

TP53

Test scope

n/a

Test method/ technology

MLPA or equivalent

Optimal Family Structure

n/a

Eligibility Criteria

Living affected individual (proband) where the individual +/- family history meets ONE of the criteria.
The proband has:
1. Rhabdomyosarcoma (≤ 5 years),
2. Rhabdomyosarcoma of embryonal anaplastic subtype (any age)
3. Adrenocortical cancer (any age),
4. Choroid plexus cancer (any age),
5. Breast cancer (≤ 30 years),
6. Triple positive breast cancer (≤ 35 years),
7. Hypodiploid acute lymphoblastic leukaemia (<18 years) 8. SHH medulloblastoma (<18 years) 9. Jaw osteosarcoma (<18 years) 10. ≥2 LFS-related cancers (both occurring ≤ 46 years; two breast cancers not eligible), 11. ≥1 LFS-related cancer with ≥1 first / second degree relative with ≥1 LFS-related cancer (one case ≤ 46 years, the other case ≤ 56 years; two breast cancers not eligible), 12. Cancer with ≥2 first / second degree relatives with cancer; across the family there is: i. 1 individual with sarcoma ≤ 45 years, AND ii. 1 individual with any cancer ≤ 45 years, AND iii. 1 individual with either a sarcoma OR any cancer occurring ≤ 45 years Deceased affected individual (proband) where (i) the individual +/- family history meets one of the above criteria, (ii) appropriate tissue is available (tumour or normal), and (iii) no living affected individual is available for genetic testing LFS-related cancers comprise: soft tissue sarcomas, osteosarcomas, adrenocortical carcinoma, central nervous system tumours and breast cancers. NOTE: The proband's cancer and majority of reported cancers in the family should have been confirmed Genetic testing may occasionally be appropriate outside these criteria following discussion at a specialist MDT with a cancer geneticist present

Commissioning group

Specialised

Overlapping idications

• The relevant cancer clinical indication (M coded) should be used for somatic testing (TP53)

Address for samples/request forms

North Thames GLH, Rare & Inherited Disease Genomic Laboratory
Specimen Reception, Level 5 Barclay House, 37 Queen Square,
London WC1N 3BH

Contact with queries

gos-tr.norththamesgenomics@nhs.net

Supporting documents

Rare Disese WGS Clinician pack

Education resources

n/a

Service updates

n/a

Request form download

Consent record

See consent guidance in test request form

Sample requirements

See sample guidance in test request form